About OncoSeer Diagnostics, Inc.
OncoSeer Diagnostics, Inc. is a UT Southwestern spin-out founded in 2022, developing multimarker blood tests to predict, monitor, diagnose, and treat immune-related adverse events (irAE) in patients receiving immune checkpoint inhibitor (ICI) therapy.
Developing multimarker blood tests for predicting immune-related adverse events (irAE) in cancer immunotherapy patientsCollaborating with UT Southwestern Medical Center (UTSW)Publishing in prominent peer-reviewed journalsAnalyzing immune dysregulation and autoantibody changes related to irAEs
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to OncoSeer Diagnostics, Inc. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.